Axcella Health - AXLA Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXLA shares.
View AXLA analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month target prices for Axcella Health's shares. Their AXLA share price forecasts range from $2.00 to $8.00. On average, they expect the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 1,153.6% from the stock's current price.
View analysts price targets for AXLA or view top-rated stocks among Wall Street analysts.

Axcella Health's stock was trading at $0.3275 at the beginning of 2023. Since then, AXLA shares have increased by 27.9% and is now trading at $0.4188.
View the best growth stocks for 2023 here.

Axcella Health saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,860,000 shares, an increase of 48.8% from the February 13th total of 1,250,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is currently 1.1 days. Currently, 7.0% of the company's shares are sold short.
View Axcella Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AXLA earnings forecast.

Axcella Health Inc. (NASDAQ:AXLA) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.04.

5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA).

(AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO.

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Axcella Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Flagship Pioneering Inc. (39.77%), Geode Capital Management LLC (0.33%), Millennium Management LLC (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane, Ventures Fund Iv LP Flagship and William Hinshaw.
View institutional ownership trends.

Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXLA stock can currently be purchased for approximately $0.42.

Axcella Health (NASDAQ:AXLA) has a market capitalization of $30.81 million. The company earns $-64,630,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243.